EUCTR2017-000506-37-IT进行中（未招募）1 期
CareCN: A phase I/II, open label, escalating dose study to evaluate safety and efficacy of an intravenous injection of GNT0003 (Adeno-associated Viral Vector expressing the UGT1A1 transgene) in patients with severe Crigler-Najjar syndrome requiring phototherapy - CareC
GENETHO0 个研究点目标入组 17 人开始时间: 2021年1月5日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 17
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •[1] Patients with severe Crigler-Najjar syndrome requiring phototherapy
- •[2] Molecular confirmation of mutations in the UGT1A1 gene by DNA sequencing
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 7
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 1
排除标准
- •[1] Fibrosis score = 3 (METAVIR) or 10 kPa
- •[2] Patients who underwent liver transplantation
研究者
相似试验
进行中（未招募）
1 期
Gene Therapy for Crigler Najjar Syndromesevere Crigler Najjar syndrome in patients requiring phototherapyMedDRA version: 20.0Level: PTClassification code 10011386Term: Crigler-Najjar syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2017-000506-37-FRGenethon17
进行中（未招募）
1 期
Gene Therapy for Crigler Najjar Syndromesevere Crigler Najjar syndrome in patients requiring phototherapyMedDRA version: 20.0Level: PTClassification code 10011386Term: Crigler-Najjar syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2017-000506-37-NLGenethon17
进行中（未招募）
不适用
A phase I/II, open label, escalating dose, pilot study to assess the effect, safety, tolerability and pharmacokinetics of multiple subcutaneous doses of PRO051 in patients with Duchenne muscular dystrophyMedDRA version: 9.1Level: LLTClassification code 10013801Term: Duchenne muscular dystrophyDuchenne Muscular DystrophyEUCTR2007-004819-54-NLProsensa Holding B.V.18
进行中（未招募）
1 期
A study to assess the effect and safety of multiple subcutaneous doses of drisapersen in patients with Duchenne DiseaseDuchenne Muscular DystrophyMedDRA version: 17.1Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2007-004819-54-BEProsensa Therapeutics BV12
进行中（未招募）
1 期
A study to assess the effect and safety of multiple subcutaneous doses of drisapersen in patients with Duchenne DiseaseDuchenne Muscular DystrophyEUCTR2007-004819-54-SEProsensa Therapeutics BV12